Open Access

Ryanodine receptors: physiological function and deregulation in Alzheimer disease

Molecular Neurodegeneration20149:21

https://doi.org/10.1186/1750-1326-9-21

Received: 14 January 2014

Accepted: 18 May 2014

Published: 5 June 2014

Abstract

Perturbed Endoplasmic Reticulum (ER) calcium (Ca2+) homeostasis emerges as a central player in Alzheimer disease (AD). Accordingly, different studies have reported alterations of the expression and the function of Ryanodine Receptors (RyR) in human AD-affected brains, in cells expressing familial AD-linked mutations on the β amyloid precursor protein (βAPP) and presenilins (the catalytic core in γ-secretase complexes cleaving the βAPP, thereby generating amyloid β (Aβ) peptides), as well as in the brain of various transgenic AD mice models. Data converge to suggest that RyR expression and function alteration are associated to AD pathogenesis through the control of: i) βAPP processing and Aβ peptide production, ii) neuronal death; iii) synaptic function; and iv) memory and learning abilities. In this review, we document the network of evidences suggesting that RyR could play a complex dual “compensatory/protective versus pathogenic” role contributing to the setting of histopathological lesions and synaptic deficits that are associated with the disease stages. We also discuss the possible mechanisms underlying RyR expression and function alterations in AD. Finally, we review recent publications showing that drug-targeting blockade of RyR and genetic manipulation of RyR reduces Aβ production, stabilizes synaptic transmission, and prevents learning and memory deficits in various AD mouse models. Chemically-designed RyR “modulators” could therefore be envisioned as new therapeutic compounds able to delay or block the progression of AD.

Keywords

Ryanodine receptor Calcium Alzheimer disease Endoplasmic reticulum Neurodegeneration Presenilin Amyloid precursor protein Amyloid beta

Introduction

Alzheimer Disease (AD) is the most common type of dementia characterized clinically by progressive deterioration of cognitive functions including memory, reasoning, and language [1]. Neuropathological hallmarks of the disease include extracellular amyloid plaques mainly composed of a set of hydrophobic peptides referred to as β-amyloid peptides (Aβ) aggregates and intracellular neurofibrillar tangles (NFT) composed of hyperphosphorylated microtubule-associated tau protein [24]. Aging is the major risk factor for the most common late-onset cases AD. However, a significant number of aggressive cases generally characterized by an earlier onset are inherited in an autosomal dominant manner (FAD) [5, 6], and caused by mutations on the β-Amyloid precursor protein (βAPP, the precursor of the Aβ peptides) [7] and on presenilins (PS1 and PS2) (catalytic core components of the βAPP cleaving enzyme γ-secretase [2, 3]) (Figure 1). Interestingly, both mutations in PS1-2 and βAPP proteins either modify the nature of Aβ peptides and/or affect the levels of their production [8, 9].
Figure 1

Amyloidogenic and non-amyloidogenic pathways of β amyloid precursor protein (βAPP) processing. Aβ peptides are derived from the processing of the βAPP through the amyloidogenic pathway, implicating β-secretase (BACE1) and γ-secretase complex (composed of PS1 or PS2, Nicastrin, anterior pharynx-defective-1 (APH-1), and presenilin enhancer-2 (PEN-2)). Aβ production is abolished when βAPP is processed through the non-amyloidogenic pathway implicating α-secretase and γ-secretase complexes.

Calcium (Ca2+) is a ubiquitous signal transduction molecule. It plays a key role in the modulation of neuronal activity and is involved into a wide array of cellular signals regulating various critical processes, such as cell growth, differentiation, metabolism, exocytosis, and apoptosis [10]. In neurons, the elevation of cytosolic Ca2+ concentration ([Ca2+]i) triggers the release of neurotransmitter at synaptic junctions and contributes to dendritic action potential, regulates the activity-dependent changes in gene expression, as well as synaptic plasticity [11]. Cytosolic Ca2+ levels are kept in a very low range (≈100 nM) compared with the levels present in the extracellular space (≈2 mM) or inside intracellular stores (≈100-500 μM), where the endoplasmic reticulum (ER) represents the major dynamic Ca2+ intracellular pool [12]. Neuronal Ca2+ signaling implicates a complex interplay between Ca2+ entry through the plasma membrane and release from the ER (Figure 2). The ER is a continuous and highly motile network distributed throughout the neuron within dendrites and dendritic spines, axons and presynaptic nerve terminals, as well as in growth cones [13] and supports diverse functions within each of these cellular compartments [14]. Thus, in dendrites, ER Ca2+ release is involved in modulating postsynaptic responses and synaptic plasticity [15]; in axon terminals, it is involved in vesicle fusion and neurotransmitter release [16]; in the soma, it is coupled to the activation of Ca2+-sensitive signaling pathways such as kinase and phosphatase activities [11]; and in the perinuclear space, it can trigger gene transcription [17]. Ca2+ mobilization from the ER is also important in growth cone activity involved in the formation of new connections and/or the strengthening of preexisting connections that occur during learning and memory in the adult brain [18].
Figure 2

Neuronal Ca 2+ signaling. Cytosolic [Ca2+]i rises are the result of an influx across the plasma membrane via voltage-gated Ca2+channels (VGCCs), ionotropic glutamate receptors (N-Methyl-D-Aspartic acid receptors, NMDARs; and alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate, AMPARs), and the release from the ER through the inositol 1,4,5-trisphosphate (IP3R) and the ryanodine (RyR) receptors. Intraneuronal Ca2+ compartmentalization, is also maintained by the activity of Ca2+-binding buffering proteins (e.g., calbindin and parvalbumin), and regulated within signaling microdomains which involve, ATP-dependent Ca2+ pumps SERCA (Sarco-Endoplasmic Reticulum Ca2+ ATPase) accumulating Ca2+ from the cytosol to ER, and the sodium-Ca2+ exchanger (Na+/Ca2+), which act together with PMCA (Plasma Membrane Ca2+ ATPase) to restore [Ca2+]i back to resting levels by extruding Ca2+ from the cytosol to the extracellular space. Although much of the Ca2+ entry into neuron is predominantly mediated by plasma membrane channels, IP3R- and/or RyR-mediated Ca2+ release can be subsequently recruited via the phenomenon of Ca2+-induced Ca2+ release (CICR), a regenerative process in which Ca2+ enhances its own release from IP3R and RyR.

The hypothesis that Ca2+ homeostasis perturbation could play a pivotal role in cascading events to AD was introduced more than 20 years ago [19]. Data obtained from experiments on dissociated cells, brains slices, and more recently and importantly on live AD animal models confirmed this hypothesis [2023]. Data are now converging to demonstrate the important role of ER Ca2+ deregulation in AD [24, 25]. In this review, we will specifically highlight how primary alterations of the expression and function of the ryanodine receptor (RyR) Ca2+ channels may play a key role in the setting of histopathological lesions, alteration of synaptic plasticity, and learning and memory deficits that are associated with the late stages of the disease and how these receptors may interplay with secretases expression and function and βAPP catabolites.

Review

RyRs expression and structure

RyRs are a family of three known mammalian isoforms: RyR1, RyR2, and RyR3 which are classified as “skeketal muscle”, “heart” and “brain” types, respectively with respect to their major tissue distribution although all isoforms can be found in the brain. Thus, RyR1 is expressed at low levels in cerebellum and Purkinje cells. RyR2 is predominantly expressed in Purkinje cells of cerebellum and cerebral cortex, and in dentate gyrus of the hippocampus. RyR3 has been detected in hippocampal CA1 pyramidal cell layer, the basal ganglia, and olfactory bulbs [26].

RyRs are homotetramers with a total molecular mass of about 2 MDa. Each subunit of the receptor is a compound with a molecular mass of about 565 kDa, with the 4/5 of the channel comprising an huge N-terminal cytoplasmic domain that serves as a scaffold for channel regulators while the remaining domain is in the ER lumen [27].

RyRs pharmacology and regulation

Ca2+ activates all RyRs at low nanomolar concentrations with RyR1 > RyR2 > RyR3 in term of sensitivity to cytosolic free [Ca2+] [28, 29]. Caffeine and ryanodine are pharmacological modulators of RyRs. Caffeine freely diffuses through the plasma membrane and subsequent cell excitation can be directly monitored by its ability to quench the fluorescence of various Ca2+ sensors in a wavelength-independent manner [30]. All structures of neurons, from soma to dendrites and presynaptic terminals, respond to caffeine. Caffeine induces a [Ca2+]i rise without a requirement for extracellular Ca2+, and the [Ca2+]i elevation is not associated with plasmalemmal Ca2+ movements. Caffeine-evoked [Ca2+]i elevations are sensitive to pharmacological modulators interacting with RyRs or with SERCA pumps. Thus, these [Ca2+]i responses are blocked by ryanodine, ruthenium red, and procaine and disappear after inhibition of SERCA-dependent ER Ca2+ uptake with thapsigargin (TG) or cyclopiazonic acid (CPA) [30]. Caffeine-induced Ca2+ release that is sensitive to TG and ryanodine has even been observed in individual spines of cultured hippocampal neurons, which are rich in RyR [31]. Ryanodine locks the RyR channel to an “open state” at low concentrations (<10 nM) and to “closed state” at higher concentrations (>100 μM) [32]. The activity of RyRs is also inhibited by mM concentrations of Mg2+ and μM concentrations of ruthenium red [3234]. Dantrolene is well known inhibitor of RyRs. It was first characterized as a skeletal muscle relaxant [35], and is widely used in anesthesiology practice and in treating malignant hyperthermia (MH) [36]. Dantrolene was described to be bind to amino acids 590–609 of RyR1 isoform, which presumably stabilizes the channel protein, thus providing evidence for a direct action of dantrolene on RyRs [37, 38]. This stabilizing effect inhibits aberrant activation of the channel and prevents excessive Ca2+ release from intracellular stores. Different papers also tend to show that dantrolene binds to the corresponding sequence (amino acids 601–620) of RyR2 [39, 40]. Recent evidence has suggested that dantrolene may ameliorate abnormal RyR2-mediated Ca2+ release associated with heart failure [4143]. It is worth to mention that the specificity of dantrolene towards RYRs has been debated in a recent review [23], since azumolene, an equipotent dantrolene analog, inhibits a component of SOCE coupled to activation of RyR1 by caffeine and ryanodine [23, 44].

RyRs are also directly or indirectly modulated by other channels and kinases [45]. Calmodulin (CaM), a 17 kDa Ca2+ binding protein, binds to RyR1 at Cys3635 and to the corresponding region on RyR2, 3578–3603. CaM can either activate or inhibit RyR1 depending on Ca2+concentrations but appears to preferentially inhibit RyR2 [45, 46]. The 12 and 12.6 kDa FK506 binding proteins (FKBP12 and FKBP12.6) known also as Calstabin1 and Calstabin2 bind to, and stabilize the closed state of RyR1 and RyR2, respectively, and are essential for coupled gating of RyR channels [47]. Ca2+/calmodulin-dependent protein kinase II (CaMKII) associates with, phosphorylates, and regulates the activity of RyR in the heart and skeletal muscle [48]. RyRs may also be regulated by Sorcin, a cytosolic Ca2+-binding protein [49], and by Calsequestrin (CSQ), a low affinity, high capacity luminal Ca2+ buffering protein [50]. Different studies reported that mutations in RyR or alterations in the post-translational modifications of RyRs (i.e. hyper-phosphorylation, -oxidation, and -nitrosylation) can shift RyRs from a finely regulated state to an unregulated Ca2+ leak channel. RyR “leaky” channels alter cell physiology and are associated with different pathological states in muscle and non-muscle cells [5155].

Overview of Ca2+dysregulation in AD

Alteration of Ca2+ signals in AD were largely linked to the “amyloid hypothesis” where the modification of the nature, levels, biophysical properties and subcellular localization of Aβ peptides in various areas of the brain is believed to contribute to a molecular dysfunction culminating in neuronal death and dementia. A large number of studies also revealed the potent implication of PS as major contributor to Ca2+ deregulation in AD. The data listed below summarize the major findings obtained in this field:
  1. I.

    In vivo imaging of Ca2+ transients in APP/PS1 (APPswe/PS1-ΔE9) mice model revealed that about 20% of transgenic mice dendrites and axons harbor moderate to severe [Ca2+] elevation than wild type mice, and that the severity of Ca2+ overload correlates with the structural integrity of the dendrite or axon. It was suggested that [Ca2+] elevation may depend on the Aβ accumulation since Ca2+ transients were not observed in animals without cortical plaques (i.e. young APPswe and PS1 mutant mice) [56]. Another group reported a more complex alteration of Ca2+ transients in a different AD mice model (APPswe/PS1G384A) by showing a spatial distribution of silent neurons (decreased Ca2+ signals) (29%) and hyperactive neurons (increased Ca2+ signals) (21%) in transgenic mice brain as compared to wild type mice brain. In accordance with the paper by Kuchibhotla et al., they also proposed that the neurons hyperactivity occur near Aβ plaques [57].

     
  2. II.

    Exogenous application of synthetic A&#x03B2; peptides or oligomeric agregates leads to elevated levels of [Ca2+]i [58, 59]. Aβ-mediated changes in [Ca2+]i occur likely through Aβ ion channels incorporation in the cell membrane, changes in membrane permeability, and phosphatidylserine asymmetry [60, 61]. Actually, in addition to promoting influx of extracellular Ca2+ [62], Aβ oligomers potently evokes Ca2+ signals through its release from the ER [58, 6365]. Another mechanism underlying Aβ-mediated elevated Ca2+ entry was recently revealed by renner et al. showing that soluble Aβ oligomers accumulation at the synapse recruited mGluR5 thus elevating intracellular Ca2+ [66]. It is important to emphasize that the level of exogenously applied Aβ, used in these studies, is orders of magnitude above physiological levels. Thus, the relevance of Aβ-mediated Ca2+ signaling deregulation is provided in experiments using in vitro and in vivo AD models overproducing endogenously Aβ (see details in item IV).

     
  3. III.

    Mutations of PS1 and PS2 had a significant impact on Ca2+ signaling in AD models. Actually, PS may directly alter ER Ca2+ signaling and affect activity and/or expression of many proteins involved in ER Ca2+ signaling deregulation in AD. Several studies showed that PS mutations induce exacerbated IP3R- and RyR- mediated Ca2+ release [6772], and alter the function of the SERCA pump [73]. This has been documented in fibroblasts isolated from FAD patients, in cellular systems expressing wild type and mutated PS and in hippocampal and cortical neurons of AD mice [67, 68, 7072]. PS were also shown to support ER Ca2+ leakage [74, 75], likely through their function as low conductance, passive ER Ca2+ leak channels, independently of their γ-secretase activity [74, 7679]. Even if PS-mediated ER Ca2+ leak was recently debated [80, 81], recent data obtained by other laboratories and using different systems tend now to confirm the leak function of PS [82, 83].

     
  4. IV.

    Other studies have identified &#x03B2;APP-mediated changes to ER Ca2+ signaling related to Amyloidogenic processing of βAPP. Decreased production of sAPPα (soluble APPα fragment: derived from non-amyloidogenec processing of βAPP) (Figure  1), was shown to activate K+ channels [84]. The transcription regulatory factor AICD (APP intra-cellular domain: derived from both amyloidogenic and non-amyloidogenic βAPP processing) (Figure  1) may affects Ca2+ hormeostasis by regulating the expression of genes involved in Ca2+ homeostasis [8587], namely the transient receptor potential cation channel subfamily C member 5 (TRPC5), a component of receptor-activated nonselective Ca2+ permeant cation channel [88]. Additional studies support the physiological role of βAPP in Ca2+ homeostasis by demonstrating that βAPP downregulation enhances both Ca2+ content of the ER and acidic stores and the dynamics of store operated Ca2+ channel activity [89]. As for PS, βAPP FAD mutations were also shown to alter Ca2+ signals. It has been documented that fibroblasts from AD patients harboring the Swedish double mutation (βAPPswe: βAPPK670N/M671L) showed reduced bombesin-induced intracellular Ca2+ elevations compared to controls while all other pools of Ca2+ were unaffected [90]. Primary cortical neurons from TgCRND8 mice carrying combined βAPPswe and Indiana (βAPPV717F) mutations show elevated ER release of Ca2+ [91]. In accordance with these findings, we recently reported a global alteration of Ca2+ homeostasis in human neuroblastoma SH-SY5Y cells overexpressing human wild type βAPP or βAPPswe. This Ca2+ alteration is manifested by an increase in cytosolic Ca2+ signals associated to enhanced ER Ca2+ passive leakage, and large IP3R- and RyR-mediated Ca2+ release as compared to control cells, and to increased VGCC permeability to Ca2+ [92].

     

A focus on Ryanodine Receptors-mediated Ca2+signals deregulation in AD

Several studies addressed the role of RyR-mediated Ca2+ disruptions in AD models (Table 1). It was shown that the RyR blocker dantrolene reversed carbachol-induced elevation of Ca2+ release in human neuroblastoma SH-SY5Y cells expressing PS1 mutants (PS1M146V, and PS1L250S) [93]. Accordingly, it was also reported that the RyR agonist caffeine evoked larger Ca2+ liberation in primary cultured neurons derived from the triple transgenic mice model 3xTg-AD (knock in for the mutated PS1M146V, and overexpressing mutated βAPP and microtubule-associated tau protein (PS1M146V/APPswe/tauP30IL)), and the transgenic knock in mice model expressing mutated PS1 (PS1M146V) [94]. Increased RyR channel function was further confirmed in PC12 cells expressing wild type PS1, PS1L286V, PS1M146V or PS2N141L mutants [95, 96]. Interestingly, RyR-mediated ER Ca2+ homeostasis deregulation in AD was supported by the finding showing that exacerbated IP3R-evoked Ca2+ signals in the PS1M146V- and the 3xTg-AD-derived neurons occur through increased RyR-mediated CICR (Ca2+-induced Ca2+ release) (Figure 2) [72]. Studies by the group of Bezprozvanny postulated that the large RyR-mediated Ca2+ release observed in the 3xTg-AD-derived neurons is likely associated to the impairment of PS Ca2+ leak channel function and to increased ER Ca2+ pool [78]. The emerging hypothesis form these studies is that RyR function alteration may be intimately linked to PS. However, experiments using the PScDKO mice model (PS1 and PS2 conditioned double knockout mice) lead to controversial conclusions [78, 97]. While the group of Bezprozvanny showed that primary neurons derived from PScDKO mice harbor increased ER Ca2+ pool and increased RyR-mediated Ca2+ signals [78], a recent study by Wu et al. showed that neurons derived from the same study model did not harbor alteration in ER Ca2+ content and rather display reduced RyR agonist-induced Ca2+ release from the ER and RyR-mediated synaptic responses [97]. Furthermore, the authors demonstrated that knockdown of RyR expression in wild-type hippocampal neurons mimics the defects observed for Ca2+ homeostasis and presynaptic function in PScDKO neurons [97]. These data further support previous results demonstrating a physiological role of PS in synaptic plasticity [98, 99], and that inhibition of RyR function mimics and occludes the effects of PS inactivation and intracellular Ca2+ homeostasis and synaptic dysfunction [99].
Table 1

RyR-mediated calcium deregulation in AD

AD models

Study systems

RyR-mediated [Ca2+] dysregulations

References

PS1M146V and PS1L250S

SH-SY5Y cells

Dantrolene blocked ↑ carbachol-induced [Ca2+] signals (vs. wild type PS1)

[93]

3xTgAD mice PS1M146V KI Tg mice

Primary cortical neurons

↑ caffeine-induced [Ca2+] signals (vs. wt neurons)

[94]

PS1WT, PS1L286V, PS1 M146V, PS2 N141L

PC12 cells

↑ caffeine-induced [Ca2+] signals (vs. vector transfected cells)

[95, 96]

APPwt and APPswe

SH-SY5Y cells

↑ caffeine-induced [Ca2+] signals (vs. vector transfected cells)

[92]

Tg2576 mice

hippocampal primary neurons

↑ caffeine-induced [Ca2+] signals (vs. wt neurons)

[92]

PS M146V KI Tg and 3xTgAD mice

Acute brain slice preparation (6w, 6 mo and 1.5 Y) (*)

↑ caffeine-induced [Ca2+] signals

[72, 100]

Dantrolene reduced the IP3-evoked Ca2+ responses (vs. wt-derived brain slices)

Extracellular Aβ42 application

Primary Cortical neurons

siRyR-3 blocked increased ryanodine- and glutamate-induced [Ca2+] signals upon Aβ42 application (vs. Aβ42 non-treated neurons)

[91]

PScDKO Tg and 3xTgAD mice

Primary hippocampal neurons

↑ caffeine-induced [Ca2+] signals (vs. wt-Tg neurons)

[78]

↑ ER Ca2+ pool (vs. wt-Tg neurons)

PScDKO Tg mice

Primary hippocampal neurons

↔ ER Ca2+ pool

[97]

↓ caffeine-induced [Ca2+] signals (vs. wt neurons)

PS2N141L Tg and PS2N141L/APPswe mice

Primary neuronal cultures and acute brain slice preparation

↓ ER [Ca2+]

[101]

↓ IP3-generating Ca2+ responses

↑ caffeine-induced [Ca2+] signals (vs. wt-Tg neurons)

PS1M146VKI Tg and PS1M146V/APPswe Tg mice

Acute brain slice preparation

↑ caffeine-induced [Ca2+] signals

[102]

RyR blockade prevents NMDA Ca2+ response (vs. wt-derived brain slices)

Abbreviations: [Ca 2+ ] calcium signals are depicted as ↑ (increased), ↓ (reduced), or ↔ (unchanged) as compared to respective controls, (*) study was performed on acute brain slice preparation isolated from transgenic mice at different ages (6 weeks (w), 6 months (mo) and 1.5 years (Y), vs versus, KI knock in, Tg Transgenic, wt Wild type, PScKO Tg mice are conditionally double knock out for PS1 and PS2, Tg2576 mice express the βAPP harboring Swedish double mutation (APP K670N / M671L ), 3xTgAD mice are generated from the PS1M146V KI mouse overexpressing APPswe and TauP130L.

These studies may outline a possible regulation between RyR and PS towards ER Ca2+ homeostasis. However, the mechanisms underlying this regulation are still unraveled and the basis of the contradictory results in PSDKO cells is not clear.

Another question emerging in “AD Ca2+ hypothesis” is the real impact of PSs versus PSs-mediated βAPP processing and Aβ peptides production in Ca2+ disturbances in AD models. To answer this question, in a recent study, Kipanyula and colleagues used two transgenic mice models carrying the FAD-linked PS2N141L mutation either alone or in the presence of βAPPswe mutation (PS2-APP) [101]. They reported in both PS2N141L and PS2-APP transgenic neurons a similar reduction in ER Ca2+ content and decreased response to IP3-generating agonists, albeit increased Ca2+ release induced by caffeine and increased Ca2+ excitability. Further experiments lead authors to postulate that enhanced response to caffeine in both models resulted from the increased level of RyRs observed in brains and cultured neurons derived from both transgenic mice as compared to wild-type mice [101]. The comparative analyses of both transgenic mice models lead authors to hypothesize that Ca2+ stores deregulation depend directly on the mutant PS2 itself and not on PS2-dependent APP processing or total Aβ levels (i.e. larger Aβ level was detected in PS2-APP mice as compared to PS2 mice) [101]. However, it may be argued that the Aβ increase observed in PS2 transgenic mice models may be sufficient to cause the Ca2+ alterations and that the additional larger Aβ rise observed in the PS2-APP mice have no additional effect. In this scenario, RyR dysfunction in PS2 and PS2-APP mice may also likely and predominantly dependent on a direct interaction of PS2 mutant with RyR.

Importantly, the real impact of Aβ and of βAPP overexpression and mutation on ER Ca2+ signaling and particularly on RyR dysfunction was revealed in AD-related study models independently from PS mutation or overexpression [64, 86, 91, 92, 103, 104]. Regarding βAPP overexpression and mutation, it has been documented that primary cortical neurons isolated from TgCRND8 mice (described above) display elevated RyR-mediated Ca2+ release, while global Ca2+ handling remained unaffected [91]. Accordingly, we recently highlighted a fundamental role of increased RyR-induced Ca2+ release in SH-SY5Y neuroblastoma cell line stably overexpressing either wild-type or mutated human βAPP (APP695 or APPswe respectively), and in primary neurons from APPswe-expressing mice (Tg2576) [92]. Of most interest, it was also reported that exogenous Aβ oligomers may stimulate RyR-mediated Ca2+ release in wild type hippocampal neurons [105], and that application of soluble Aβ caused a marked increase in RyR activity, resulting in a 10-fold increase in channel open probability which was blocked by RyR antagonist ruthenium red [106].

Ryanodine Receptors expression in AD

The alteration of RyR expression in AD-affected brains was first described in 1999 by Kelliher et al. [107], who showed that [3H] ryanodine binding (indicative of RyR expression protein) is elevated in hippocampal regions (subiculum, CA2 and CA1) of human post-mortem tissue at early stages of the disease, i.e. prior to extensive neurodegeneration and overt Aβ plaque deposition [107]. Recently another paper reported elevated RyR2 mRNAs levels early in mild cognitive impairment derived brains [108]. Accordingly, altered RyR2 expression was recently reported in a preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset AD [109] (Table 2).
Table 2

RyR expression in Alzheimer disease

AD samples/models

Brain regions/study systems

AD stage (*)

RyR expression (**)

References

Human AD post-mortem brains

Hippocampal regions (Subiculum, CA1, CA2)

Early stages (I-II)

↑ [3H] RyR binding

[107]

Human AD post-mortem brains

Hippocampal regions (Subiculum, CA1, CA2, CA3, and CA4)

Late stages (V-VI)

↔ [3H] RyR binding

[107]

↓RyR2 mRNA

PS1 L285V, PS1M146V mutations

PC12 cells

 

↑ RyR3 mRNA and protein

[95]

PS1M146V KI Tg mice

Primary neurons

Human AD post-mortem brains

mid frontal cortex

 

↓RyR2-3 mRNA splice variants

[108]

MCI post-mortem brains

mid temporal and mid frontal cortex

 

↑RyR2 mRNA; ↔ RyR3 mRNA

[108]

mid frontal cortex

↓RyR2 mRNA splice variant;

mid temporal cortex

↑RyR2 mRNA splice variant

Extracellular Aβ42 application

Primary cortical neurons

 

↑RyR3 mRNA;

[91]

↔ RyR1-2 mRNA

CRDN8 Tg mice

Primary cortical neurons

4-4.5 (mo)

↑RyR3 mRNA

[91]

Whole brains

↑RyR3 protein

3xTgAD mice

Primary hippocampal neurons

 

↑RyR protein

[78]

PS1M146V KI Tg mice 3xTgAD mice

Whole brains

6 (w)

↑RyR protein

[72, 110]

6 (mo)

↔ RyR protein

1.5 (Y)

↑RyR protein

3xTgAD mice

Hippocampus

6-8 (w)

↑RyR2 mRNA;

[94, 100]

↔ RyR1-3 mRNA

Tg2576 mice

Cortex

15-18 (mo)

↑RyR2 mRNA;

[92]

↔ RyR1-3 mRNA

↑RyR proteins

APPWt and APPswe mutation

SH-SY5Y cells

 

↑RyR1-2-3 mRNA

[92]

↑RyR proteins

PScDKO Tg mice

Hippocampus

2 (mo)

↓ RyR proteins

[97]

↓ [3H] RyR binding

↔ RyR mRNA

Subletal Aβ oligomers

Primary hippocampal neurons

 

↓ RyR 2–3 mRNA

[105]

↓ RyR 2 protein

APPswePS1L166P Tg mice

Hippocampus

3 and 6 (mo)

↑RyR 2–3 protein

[111]

Abbreviations: (*) AD stage is defined following BRAAk’s staging for human AD post-mortem brains, and is referred in weeks (W), months (mo) or years (Y) in AD mice models, (**) RyR expression (mRNA or protein level) is depicted as ↑ (increased), ↓ (reduced), or ↔ (unchanged) as compared to respective controls, PS presenilin, MCI mild cognitive impairment, KI knock in, Tg transgenic, Wt wild type, CRDN8 Tg mice express human APP with a double mutation (APPK670N/M671L + APPV717F), PScKO Tg mice are conditionally double knock out for PS1 and PS2, Tg2576 mice express the Swedish double mutation (APP695K670N/M671L), 3xTgAD mice are generated from the PS1M146VKI mouse overexpressing APPswe and TauP130L.

Interestingly, alteration of RyR expression was reported in different AD study models and was shown to be linked to Aβ and/or overexpression of PS mutants. Thus, increased expression of RyR3 but not RyR1 or RyR2 was observed in cortical neurons isolated from C57Bl6 mice upon extracellular Aβ42 application [91], and in cortical neurons and brain tissue from TgCRND8 mice [91]. We recently showed that RyR protein and mRNAs levels are increased in neuroblastoma SH-SY5Y cells overexpressing wild type βAPP or βAPPswe and in Tg2576 mice as compared to respective control mice [92] (Table 2).

Increased RyR expression was also largely reported in AD models where PS is overexpressed or mutated. Elevated RyR mRNAs and protein was first reported in in vitro models expressing PS1 mutants [95]. Importantly, RyR expression increases throughout the lifetime of the PS1M146V, and the 3xTg-AD transgenic mice [72, 94, 100]. Recent findings of Liu et al. further support these observations by showing increased expression of both RyR2 and RyR3 in APPswePS1L166P transgenic mice [111]. It was proposed that the induction of RyR expression is a compensatory event linked to the loss of PS leak function [78]. This hypothesis was recently debated in a study using PSDKO mice model, where authors revealed that the absence of PS, on the contrary, triggers an hippocampal reduction of RyR protein levels [97]. The basis of the contradictory results about RyR expression in AD models may be linked to a variable regulation of RYR along AD pathology development and between brain areas. As a matter of fact, reduction of RyR2 and RyR3 mRNA levels and RyR2 protein expression was observed upon treatment with sublethal concentrations of Aβ oligomers [112]. Kelliher, M. et al. [107] also reported a complex regulation of RyR expression in human AD brains where RyR expression was shown to be elevated in hippocampal regions in cases with early neurofibrillary pathology and reduced in the subiculum, and CA1-CA4 regions of the late stages [107] (Table 2).

The molecular mechanisms that could underlie the regulation of RyR expression in AD are still unknown. ER stress is induced during AD, and has been indirectly implicated as a mediator of Aβ neurotoxicity [113]. In this context, it was demonstrated that Aβ triggered the activation of the ER stress response factor X-box binding protein 1 (XBP1), thereby yielding its transcriptionally spliced active form XBP1s. XBP1s showed neuroprotective activity towards Aβ oligomers through a reduction of cytosolic Ca2+ and of the expression of RyR3 [114]. Human and murine RyR3 contains multiple XBP1s binding sites [114]. It is however still unclear whether the regulation of RyR3 by XBP1 is direct or indirect. Additional work is necessary to demonstrate these observations.

The molecular link between Ryanodine Receptors and presenilins

In many cases, the adverse effects of PS mutations on Ca2+ homeostasis were associated to RyR channels activity alteration. However, the molecular mechanism underlying this regulation is not fully understood. Nevertheless, RyRs were shown to co-localize with PSs at the ER membrane [96]. Co-immunoprecipitation experiments also unraveled a physical interaction between PS1-2 and RyR2 [95, 96, 115]. The laboratory of Peter Koulen further investigated the possible physical interaction of PS with RyR and studied in vitro the impact of such interaction on RyR channel activity. In two different studies, they demonstrated that PS1 and PS2 N-termini fragments strongly increased both mean currents and open probability of single brain RyR channels [116, 117]. They proposed that PS1 NTF (1–82) and PS2 NTF (1–87) may interact with the cytoplasmic side of RyR and allosterically potentiates RyRs in a Ca2+-dependent manner [116, 117]. Another group demonstrated the molecular interaction of the large hydrophylic C-terminal region of PS2 with sorcin, a modulator of RYR channel, in human derived neuronal cell line and in brain tissues. Their data also suggested that PS2/sorcin interaction is potentiated by Ca2+ [118]. This observation was further confirmed in another cellular system where PS2, sorcin, and RyR2 were shown to physically interact (in a Ca2+ dependent manner) in both HEK-293 cells overexpressing these proteins and in mouse hearts [115].

All together this set of data demonstrates that PS may play an important role in RyR channel activity directly through the interaction of PS with RyR and indirectly through the interaction of PS with RyR modulators. However, the implication of such RyR channel function regulation by PS for AD remain to be elucidated (i.e. study of PS1-2 mutants physical interaction with RyR and the potential effect of such interactions on RyR channel activity).

Post-translational Ryanodine Receptors modification in AD: just a hypothesis

Enhanced RyR-mediated ER Ca2+ depletion may be linked to pathophysiological post-translational modifications in the macromolecular complex containing RyR1 or RyR2 resulting in “leaky channels” [45]. Interestingly, post-translational modifications of RyR2 were reported in cerebral ischemia [119] where endogenous RyRs undergo S-nitrosylation and S-gluthathionylation processes that resulted in high activity channels and ultimately lead to cortical neuronal death [119]. Disrupting function of FKBP1b, a RYR2 stabilizer, was recently shown to alter Ca2+ homeostasis in hippocampal neurons and to trigger the aging phenotype of Ca2+ deregulation in young animals (i.e. enhanced ryanodine sensitive AHP “after hyperpolarization” signals, and increased CICR from RyR) [120]. Recently, Liu et al. described the contribution of “leaky” RyR2 to stress-related memory impairments [55]. Through a series of biochemical, neurophysiological, and behavioral assays, the study demonstrated that chronic stress can affect RyR2 function through PKA hyperphosphorylation, oxidation, and nitrosylation leading to the physical dissociation of FKBP12.6/1b (calstabin2) and RyR2, thereby inducing Ca2+ leak from RyRs and cognitive dysfunction [55].

Post-translational modifications of RyRs in AD have not been reported yet. However, AD brains manifest excessive generation of reactive nitrogen (RNS) and oxygen (ROS) species, contributing to neuronal cell injury and death via a series of redox reactions [121123]. In addition, PKA activation was shown to be implicated in AD through the regulation of βAPP processing [124126], Aβ-mediated cell death in vitro and in vivo [127, 128], and oxidative stress. It is intriguing to note that RyR hyperphosphorylation is largely linked PKA activation [55, 129]. Interestingly, a microarray analysis performed on CA1 hippocampal gray matter of Alzheimer and control subjects revealed the correlation of a down regulation of the expression of RyR stabilizers namely, FKBP1a with incipient AD, suggesting an additional mechanism involved in RyR dysfunction in AD [130]. All over, these observations must stimulate the initiation of dedicated studies investigating the influence of RyR destabilization in the onset and/or progression of AD.

Ryanodine Receptors and βAPP processing

It was reported that Ca2+ homeostasis may influence βAPP pathophysiological processing. Thus, Aβ production is enhanced by elevation of intracellular [Ca2+]i [131, 132] and RyR-mediated Ca2+ release [133], and is reduced in IP3R-deficient lines [67]. Of particular interest, we showed that dantrolene-induced lowering of RyR-mediated Ca2+ release leads to the reduction of βAPP cleavage by β- and γ-secretases and decreases both intracellular and extracellular Aβ load in wild type βAPP- or βAPPswe- overexpressing neuroblastoma cells as well as in primary cultured neurons derived from Tg2576 mice brain. We also demonstrated that this Aβ reduction could be accounted for by decreased Thr-668-dependent βAPP phosphorylation and lowered β- and γ-secretases activities [92]. Importantly, we and other laboratories showed that dantrolene diminishes Aβ load, and reduces Aβ-related histological lesions in three different AD mice models (Tg2576, 3xTg-AD and PS1M146V/APPswe), demonstrating that subchronic blockade of RyR activity may be beneficial in the context of AD [92, 134, 135]. On the contrary, long-term feeding of dantrolene was shown to increase Aβ load in APPswePS1L166P transgenic mice [78].

Discrepancies in the above-described data may rely on the kinetics of AD-like set-up and progression as well as the duration of RyR blockade specifically linked to various models examined. These puzzling results may also point out a possible dual protective/compensatory versus pathogenic role of RyR at different stages of the development of AD.

The recent paper by Bezprozvanny’s group sheds new lights on this complex dual role of RyR in the development of AD [111]. Authors used a genetic approach to modulate RyR expression along AD development in APPswePS1L166P mice and generated APPPS1xRyR3−/− mice as a study model. They demonstrate that the deletion of RyR3 in young APPPS1 mice elevates Aβ accumulation, and increases hippocampal neuronal network excitability thus accelerating AD pathology. In contrast, the deletion of RyR3 in older APPPS1 mice reduces Aβ plaques, and rescues the network excitability and the loss of mushroom spines [111].

All together, these studies suggest a complex dual role of RyR in AD pathology. RyR may function as a compensatory/protective actor at early disease stages, and acts as a pathogenic molecular determinant contributing to the setting of histopathological lesions and synaptic deficits observed at the late disease stages.

Ryanodine Receptors and neurodegeneration

RyR-mediated ER Ca2+ release leads unequivocally to large cytosolic Ca2+ signals. Thus, it could be postulated that enhanced RyR-mediated Ca2+ release may be indirectly implicated in neuronal death through cytosolic Ca2+ overload. Indeed, pharmacological targeting of RyR by its specific inhibitor, dantrolene suggested that this receptor could play a direct role in neurodegeneration. Popsecu et al. showed that dantrolene protected neurons against kainic acid-induced apoptosis in vitro and in vivo [136]. Neuroprotective effect of dantrolene was also reported in cerebral ischemia [137, 138], and in different neurodegenerative diseases such as Huntington’s disease [139, 140], and spinocerebellar ataxia of types 2 and 3 [141, 142]. Dantrolene was shown to reduce the glutamate-induced increases in intracellular [Ca2+], and protects against glutamate-induced neurotoxicity [143]. Complete block of glutamate toxicity by dantrolene was also observed in the absence of extracellular Ca2+, which indicates that Ca2+ release from intracellular stores is essential for the propagation of glutamate-induced neuronal damage [144].

Related to AD, intracellular Ca2+ levels were increased in cells expressing the human PS1L286V mutation. Aβ induced cell death in these cells and dantrolene protected the cells against these deleterious effects [145]. Imaizumi et al. showed that treatment of rat cortical neurons with Aβ increased the expression DP5, a neuronal apoptosis-inducing gene [146]. Induction of DP5 gene expression was blocked by dantrolene suggesting that the induction of DP5 mRNA occurs downstream of the increase in cytosolic Ca2+ concentration caused by Aβ. Moreover, DP5 specifically interacts with Bcl-xl during neuronal apoptosis following exposure to Aβ, and its binding could impair the survival-promoting activities of Bcl-xl [146]. Accordingly, dantrolene treatment protected PC12 cells expressing PS2N141L mutant from death induced by L-glutamate and Aβ toxic peptides [96]. The direct implication of RyR in neuronal death was also proposed by Supnet et al. who showed that suppression of RyR3 expression in TgCRND8 neurons, increased neuronal death [91, 147], thus supporting a protective role of RyR in the late stages of AD pathogenesis, at least in this mice model. According to this, other studies highlighted a potential protective role of RyR in AD models. Thus, long-term pharmacological blockade of RYR with dantrolene in APPswe/PSL166P mice resulted in the loss of synaptic markers, and neuronal atrophy in hippocampal and cortical regions [78].

Based on these results, one could assume that alteration of RyR-mediated Ca2+ signals along AD pathogenesis progression may shift cell behavior from a protective/adaptive response to a pro-apoptotic phenotype.

Dantrolene-mediated neuroprotection may accur via the modulation of Ca2+-dependent proteases and kinases. Thus calpain, CaMKII, PKA, and MAPK that are all activated by cytosolic Ca2+ control the transcriptional activation of immediate early and memory genes [148, 149]. It is noteworthy that the activated form of calpain2 is increased in neuritis and neurons at risk for developing neurofibrillary pathology and is extensively bound to neurofibrillary tangles in brain AD patients [150]. Interestingly, calpains inhibition was demonstrated to improve memory and synaptic transmission in AD models [149]. Calcineurin (Ca2+/calmodulin-dependent serine/threonine phosphatase) induces endocytosis of NMDA receptors, reduces synaptic currents and activates propoptotic molecules such as BAD [151]. Remarkably, Dinely et al. also reported that calcineurin is upregulated in the brain of Tg2576 mice model [152], and that the calcineurin inhibitor FK506 prevents the loss of mitochondrial potential induced by Aβ by preventing cytochrome C release from mitochondria [153].

Ryanodine Receptors-mediated synaptic dysfunction and learning and memory deficits in AD

Physiological role of RyR in synaptic function and memory formation and storage

Certain forms of Ca2+-dependent synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD), are thought to underlie the cellular/molecular mechanisms of learning and memory [154]. High concentration spikes of Ca2+ activate LTP. Information placed in this temporary memory is uploaded and consolidated in more permanent memory stores during certain phases of sleep. During another phase of sleep, smaller elevation in Ca2+ activates the LTD.

Pre-synaptically, CICR waves through the RyR trigger neurotransmitter release that is detected as a temporary depolarization of postsynaptic membrane potential (miniature postsynaptic potentials) [155]. CICR evoked by voltage-dependent Ca2+ entry can mobilize neurotransmitter vesicles from the reserve pool to the readily releasable pool and thus facilitate subsequent vesicle release [156]. This Ca2+-dependent release has implications for short-term forms of presynaptic plasticity known as paired pulse facilitation (PPF) [102, 155]. Post-tetanic potentiation (PTP) (another form of presynaptic plasticity that occurs following a high frequency stimulus) is also thought to involve residual Ca2+ elevation that results from RyR-mediated Ca2+ release [155, 157].

Post-synaptically, ER Ca2+ is involved in long- and short-term plasticity. Long-term changes in synaptic efficacy and plasticity depend on the combination of channels recruited in dendritic spines [158]. For example, NMDAR mediated-Ca2+ entry into spines and dendrites is essential but not sufficient for the induction of LTP [156, 159]. ER Ca2+ stores can amplify the initial NMDAR-mediated signal and determine the polarity as well as input specificity to activate downstream cascades necessary to encode LTP or LTD [159]. As a matter of fact, blocking IP3R leads to a switch of LTD to LTP and elimination of heterosynaptic LTD, whereas blocking RyR eliminates both LTP and homosynaptic LTD occurring at synapses that are activated, normally at low frequencies [160163]. Finally, type 3 RyR knockout mice were shown to harbor enhanced LTP and reduced LTD [164, 165].

Ca2+ partly regulates activity-dependent membrane excitability-sensitive K+ channels, such as SK channel, which contribute to the medium after-hyperpolarization (known also as refractory period, where in neuron membrane potential falls below the resting membrane potential). This current underlies spike-frequency adaptation, a phenomenon wherein accumulating Ca2+ entering through spiking activity reaches sufficient levels to activate hyperpolarizing K+ currents and transiently suppress membrane excitability. SK channels are largely activated by VGCC. However, IP3R- and RyR-mediated Ca2+ release were also shown to activate these channels and modify spiking patterns, thereby influencing local circuit activity [166].

RyR-mediated synaptic dysfunction in AD

Alteration of both RyR expression and function over time could have a significant effect on synaptic function that may contribute to cognitive decline. At the level of neuronal shape, augmented cytosolic Ca2+ leads to a loss of Ca2+ compartmentalization in dendritic spines and to a distortion of neurite morphologies mediated by activation of Ca2+-dependent phosphatase calcineurin [56]. Focusing on the role of RyR-mediated Ca2+ deregulation, Stutzmann’s group provided a large amount of data supporting the major role of RyR expression and function deregulation in synaptic abnormalities in AD mice models [72, 100, 135, 165168]. They first revealed that IP3-evoked membrane hyperpolarization is driven by Ca2+ liberation through RyR and enhanced coupling efficiency between RyR and Ca2+-activated K+ conductance [72, 165]. Increased RyR-evoked Ca2+ release was shown to occur within synapse-dense regions of CA1 pyramidal neurons of young 3xTg-AD mice and the double transgenic mice co-expressing mutated PS1 and βAPP (PS1M146V/APPswe) and significantly increases the amplitude of spontaneous postsynaptic potentials and the frequency of events responses in 3xTg-AD as compared to non-transgenic neurons [100, 166]. The obtained data also demonstrate that both presynaptic and postsynaptic RyR-sensitive Ca2+ stores contribute to synaptic transmission and plasticity in 3xTg-AD but not in non-transgenic mice [100, 166]. Interestingly, these signaling changes are present before Aβ formation, tau deposits, or memory deficits thus revealing RyR function alteration may represent an early pathogenic process of AD [100, 166].

Recently, by using young 3xTg-AD mice, the same laboratory showed that under control conditions, basal synaptic transmission, PPF and LTP appear similar to the non-transgenic mice. However when RyRs are blocked and enhanced CICR effect was suppressed, the AD neurons demonstrated enhanced basal synaptic transmission and altered short and long term plasticity. This may suggest that RyR-mediated Ca2+ signals have a prominent inhibitory effect in basal synaptic transmission and presynaptic neurotransmitter release in the AD mice [135, 168]. These data were further confirmed by showing that sub-chronic stabilization of ER Ca2+ signaling earlier in the disease process has beneficial effects on synaptic transmission and plasticity abnormalities in presymptomatic 3xTg-AD mice and adult PS1M146V/APPswe double transgenic mouse model, while having little effect in non-transgenic controls [135, 168].

RyR-mediated learning and memory decline in AD

Some evidences suggest that RyR expression levels may have a direct role in behavior and cognitive trait. It was shown that nicotine administration upregulates RyR2 levels in brain areas that control cognitive and motivational systems (notably the cortex and ventral midbrain) [169]. Previous works have shown that RyR mRNA and protein levels in the hippocampus are upregulated in response to spatial learning tasks [170]. In agreement with the role of RyR in synaptic plasticity, it was reported that RyR may play a role in learning and memory. Thus, RyR3 knockout mice exhibit decreased social behavior [171], and memory retention is accompanied by increased expression of RyR2 mRNA in the hippocampus of water maze-trained rats as compared to swimming controls [172].

In the context of AD, we demonstrated that dantrolene reduced Aβ burden in Tg2576 mice in vivo. The influence of dantrolene on learning and memory decline was studied by means of two complementary tests: the Morris water maze (MWM), which examines spatial memory, and the novel object recognition (NOR) paradigm, which records recognition memory. Both tests revealed alterations of both learning and memory behavior in Tg2576 mice. Chronic treatment with dantrolene does not affect learning ability in wild type mice, but restores learning ability in Tg2576 mice (MWM test), and increased the object discrimination index when compared to vehicle-treated Tg2576 mice (NOR test) [92]. According to these data, Peng et al. showed that chronic treatment with dantrolene reverses memory decline in the 3xTg-AD by using the MWM test [134].

We showed that Tg2576 mice harbor a reduced level of PSD-95 (a component of the post-synaptic density membrane associated guanylate kinase (PSD-MAGUK) scaffolding proteins) [92]. It is well established that PSD-MAGUK indirectly regulates synaptic plasticity and memory through the control of the number and compartmentalization of both AMPA and NMDA glutamate receptors around the PSD (post-synaptic density) [173]. We hypothesized that excessive RyR-mediated Ca2+ release and subsequent increased Aβ load may have contributed to PSD-95 expression decline in Tg2576 mice which may have led directly or indirectly to learning and memory decline. The recently published paper by Liu et al. is in accordance with these findings since genetic depletion of RyR in old APPPS1 mice rescued neuronal network excitability [111].

Conclusion

Obviously, this review reveals RyR as a key molecular determinant in “AD Ca2+ hypothesis”. It also highlights the molecular mechanisms that could influence RyR-mediated Ca2+ release in AD where PS and Aβ emerge as detrminant regulators of RyR expression and function alteration.

Altered RyR levels have been described early in human AD cases, in mild cognitive impairment and in various AD models [107, 108]. Accordingly, deregulation of RyR function was reported in diverse in vitro and in vivo AD study models. Data interpretation concerning some controversial results about RyR deregulation in AD must take in consideration the divergence of study systems i.e.: i) simple versus double or triple transgenic mice models; ii) primary cultures neurons and acute hippocampal slices versus neuronal derived cell lines or fibroblasts; and most importantly iii) the time course of “AD pathogenesis” development in each study model. We have also to consider that AD-associated neurodegeneration, synaptic dysfunction and cognitive decline are complex, inter-regulated and long processes where pathological and compensatory phenomenon may occur.Actually, data converge to demonstrate a complex dual role of RyR in AD acting as a potential compensatory/protective paradigm, or as a pathological hallmark amplifying the setting of histopathological lesions and synaptic deficits that are associated with the late AD stages. We provide evidences that RyR interfere with different routes leading to AD pathogenesis development through the amplification of APP metabolism and Aβ peptide production, the control of neuronal death, synaptic structure and plasticity dysfunctions and learning and memory decline (Figure 3).
Figure 3

Scheme of the implication of RyR expression and function alterations in AD. RyR-mediated AD pathogenesis occurs through Ca2+ signaling dysregulation, the amplification of βAPP metabolism and Aβ peptide production, the control of neuronal death and degeneration, synaptic dysfunction, and learning and memory decline. The functional cross talk between these AD “pathological hallmarks” places RyR at the crossroads of AD pathogenesis.

About 30 millions individuals are estimated to be affected with AD worldwide and to date no effective treatment exists to arrest disease progression. Therapeutic approaches targeting Ca2+ influx have demonstrated efficacy in animal AD models but very few have been successful in clinical trials [174, 175]. Targeting of ER Ca2+ homeostasis could be an additional therapeutic approach that merit testing. Data described above demonstrate that RyR could be envisaged as a potential new target. Therefore, we believe that it is of most interest to develop and test new RyR modulators with high specificity and affinity for RyR bioavailability as new therapeutic tools in AD.

Abbreviations

Aβ: 

Amyloid β peptide

AD: 

Alzheimer Disease

AMPA: 

α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

βAPP: 

β Amyloid precursor protein

Ca2+

Calcium

[Ca2+]cyt

Cytosolic calcium-concentration

[Ca2+]ER

Endoplasmic reticulum calcium-concentration

CICR: 

Ca2+-induced Ca2+ release

ER: 

Endoplasmic reticulum

IP3

Inositol 1,4,5-triphosphate

IP3R: 

Inositol 1,4,5-triphosphate receptor

NMDA: 

N-methyl-D-aspartate

PS: 

Presenilin

RYR: 

Ryanodine receptor

SERCA: 

Sarco-Endoplasmic reticulum Ca2+-ATPase

VGCC: 

Voltage gated Ca2+ channel.

Declarations

Acknowledgments

This work was supported by INSERM, CNRS, «Fondation pour la Recherche Médicale» (DEQ20071210550) and LECMA (Ligue Européenne Contre la Maladie d’Alzheimer to MC). This work has been developed and supported through the LABEX (excellence laboratory, program investment for the future) DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer’s disease). We acknowledge fellow support from BrightFocus foundation to D.D.P.

Authors’ Affiliations

(1)
Université de Nice Sophia Antipolis, IPMC
(2)
CNRS, IPMC
(3)
Albert Einstein College of Medicine, Bronx

References

  1. Lindeboom J, Weinstein H: Neuropsychology of cognitive ageing, minimal cognitive impairment, Alzheimer’s disease, and vascular cognitive impairment. Eur J Pharmacol. 2004, 490: 83-86. 10.1016/j.ejphar.2004.02.046.PubMedGoogle Scholar
  2. Checler F: Processing of the beta-amyloid precursor protein and its regulation in Alzheimer’s disease. J Neurochem. 1995, 65: 1431-1444.PubMedGoogle Scholar
  3. Wolfe MS: Processive proteolysis by gamma-secretase and the mechanism of Alzheimer’s disease. Biol Chem. 2012, 393: 899-905.PubMedGoogle Scholar
  4. Delacourte A, Buee L: Tau pathology: a marker of neurodegenerative disorders. Curr Opin Neurol. 2000, 13: 371-376. 10.1097/00019052-200008000-00002.PubMedGoogle Scholar
  5. St George-Hyslop PH, Tanzi RE, Haines JL, Polinsky RJ, Farrer L, Myers RH, Gusella JF: Molecular genetics of familial Alzheimer’s disease. Eur Neurol. 1989, 29 (Suppl 3): 25-27.PubMedGoogle Scholar
  6. Tanzi RE, Bertram L: Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005, 120: 545-555. 10.1016/j.cell.2005.02.008.PubMedGoogle Scholar
  7. Zhang YW, Thompson R, Zhang H, Xu H: APP processing in Alzheimer’s disease. Mol Brain. 2011, 4: 3-10.1186/1756-6606-4-3.PubMed CentralPubMedGoogle Scholar
  8. Golde TE, Cai XD, Shoji M, Younkin SG: Production of amyloid beta protein from normal amyloid beta-protein precursor (beta APP) and the mutated beta APPS linked to familial Alzheimer’s disease. Ann N Y Acad Sci. 1993, 695: 103-108. 10.1111/j.1749-6632.1993.tb23036.x.PubMedGoogle Scholar
  9. Wolfe MS: When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007, 8: 136-140. 10.1038/sj.embor.7400896.PubMed CentralPubMedGoogle Scholar
  10. Berridge MJ, Bootman MD, Roderick HL: Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003, 4: 517-529. 10.1038/nrm1155.PubMedGoogle Scholar
  11. Berridge MJ, Bootman MD, Lipp P: Calcium–a life and death signal. Nature. 1998, 395: 645-648. 10.1038/27094.PubMedGoogle Scholar
  12. Meldolesi J, Pozzan T: The endoplasmic reticulum Ca2+ store: a view from the lumen. Trends Biochem Sci. 1998, 23: 10-14. 10.1016/S0968-0004(97)01143-2.PubMedGoogle Scholar
  13. Dailey ME, Bridgman PC: Dynamics of the endoplasmic reticulum and other membranous organelles in growth cones of cultured neurons. J Neurosci. 1989, 9: 1897-1909.PubMedGoogle Scholar
  14. Berridge MJ: The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium. 2002, 32: 235-249. 10.1016/S0143416002001823.PubMedGoogle Scholar
  15. Holbro N, Grunditz A, Oertner TG: Differential distribution of endoplasmic reticulum controls metabotropic signaling and plasticity at hippocampal synapses. Proc Natl Acad Sci U S A. 2009, 106: 15055-15060. 10.1073/pnas.0905110106.PubMed CentralPubMedGoogle Scholar
  16. Emptage NJ, Reid CA, Fine A: Calcium stores in hippocampal synaptic boutons mediate short-term plasticity, store-operated Ca2+ entry, and spontaneous transmitter release. Neuron. 2001, 29: 197-208. 10.1016/S0896-6273(01)00190-8.PubMedGoogle Scholar
  17. Li W, Llopis J, Whitney M, Zlokarnik G, Tsien RY: Cell-permeant caged InsP3 ester shows that Ca2+ spike frequency can optimize gene expression. Nature. 1998, 392: 936-941. 10.1038/31965.PubMedGoogle Scholar
  18. Bandtlow CE, Schmidt MF, Hassinger TD, Schwab ME, Kater SB: Role of intracellular calcium in NI-35-evoked collapse of neuronal growth cones. Science. 1993, 259: 80-83. 10.1126/science.8418499.PubMedGoogle Scholar
  19. Khachaturian ZS: Calcium, membranes, aging, and Alzheimer’s disease. introduction and overview. Ann N Y Acad Sci. 1989, 568: 1-4. 10.1111/j.1749-6632.1989.tb12485.x.PubMedGoogle Scholar
  20. Bezprozvanny I, Mattson MP: Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci. 2008, 31: 454-463. 10.1016/j.tins.2008.06.005.PubMed CentralPubMedGoogle Scholar
  21. Supnet C, Bezprozvanny I: The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium. 2010, 47: 183-189. 10.1016/j.ceca.2009.12.014.PubMed CentralPubMedGoogle Scholar
  22. Chakroborty S, Stutzmann GE: Calcium channelopathies and Alzheimer’s disease: insight into therapeutic success and failures. Eur J Pharmacol. 2013, pii: S0014-2999 (13): 00883-2-doi:10.1016/j.ejphar.2013.11.012. [Epub ahead of print]. PMID: 24316360Google Scholar
  23. Popugaeva E, Bezprozvanny I: Can the calcium hypothesis explain synaptic loss in Alzheimer’s disease?. Neurodegener Dis. 2014, 13: 139-141. 10.1159/000354778.PubMed CentralPubMedGoogle Scholar
  24. Mattson MP: ER calcium and Alzheimer’s disease: in a state of flux. Sci Signal. 2010, 3: pe10-PubMed CentralPubMedGoogle Scholar
  25. Stutzmann GE, Mattson MP: Endoplasmic reticulum Ca(2+) handling in excitable cells in health and disease. Pharmacol Rev. 2011, 63: 700-727. 10.1124/pr.110.003814.PubMed CentralPubMedGoogle Scholar
  26. Giannini G, Conti A, Mammarella S, Scrobogna M, Sorrentino V: The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues. J Cell Biol. 1995, 128: 893-904. 10.1083/jcb.128.5.893.PubMedGoogle Scholar
  27. Zalk R, Lehnart SE, Marks AR: Modulation of the ryanodine receptor and intracellular calcium. Annu Rev Biochem. 2007, 76: 367-385. 10.1146/annurev.biochem.76.053105.094237.PubMedGoogle Scholar
  28. Murayama T, Ogawa Y: Characterization of type 3 ryanodine receptor (RyR3) of sarcoplasmic reticulum from rabbit skeletal muscles. J Biol Chem. 1997, 272: 24030-24037. 10.1074/jbc.272.38.24030.PubMedGoogle Scholar
  29. Chen SR, Leong P, Imredy JP, Bartlett C, Zhang L, MacLennan DH: Single-channel properties of the recombinant skeletal muscle Ca2+ release channel (ryanodine receptor). Biophys J. 1997, 73: 1904-1912. 10.1016/S0006-3495(97)78221-3.PubMed CentralPubMedGoogle Scholar
  30. Usachev Y, Shmigol A, Pronchuk N, Kostyuk P, Verkhratsky A: Caffeine-induced calcium release from internal stores in cultured rat sensory neurons. Neuroscience. 1993, 57: 845-859. 10.1016/0306-4522(93)90029-F.PubMedGoogle Scholar
  31. Korkotian E, Segal M: Fast confocal imaging of calcium released from stores in dendritic spines. Eur J Neurosci. 1998, 10: 2076-2084. 10.1046/j.1460-9568.1998.00219.x.PubMedGoogle Scholar
  32. Meissner G: Ryanodine activation and inhibition of the Ca2+ release channel of sarcoplasmic reticulum. J Biol Chem. 1986, 261: 6300-6306.PubMedGoogle Scholar
  33. Laver DR, Baynes TM, Dulhunty AF: Magnesium inhibition of ryanodine-receptor calcium channels: evidence for two independent mechanisms. J Membr Biol. 1997, 156: 213-229. 10.1007/s002329900202.PubMedGoogle Scholar
  34. Laver DR, Owen VJ, Junankar PR, Taske NL, Dulhunty AF, Lamb GD: Reduced inhibitory effect of Mg2+ on ryanodine receptor-Ca2+ release channels in malignant hyperthermia. Biophys J. 1997, 73: 1913-1924. 10.1016/S0006-3495(97)78222-5.PubMed CentralPubMedGoogle Scholar
  35. Snyder HR, Davis CS, Bickerton RK, Halliday RP: 1-[(5-arylfurfurylidene)amino]hydantoins. a new class of muscle relaxants. J Med Chem. 1967, 10: 807-810. 10.1021/jm00317a011.PubMedGoogle Scholar
  36. Kolb ME, Horne ML, Martz R: Dantrolene in human malignant hyperthermia. Anesthesiology. 1982, 56: 254-262. 10.1097/00000542-198204000-00005.PubMedGoogle Scholar
  37. Fruen BR, Mickelson JR, Louis CF: Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem. 1997, 272: 26965-26971. 10.1074/jbc.272.43.26965.PubMedGoogle Scholar
  38. Zhao F, Li P, Chen SR, Louis CF, Fruen BR: Dantrolene inhibition of ryanodine receptor Ca2+ release channels. molecular mechanism and isoform selectivity. J Biol Chem. 2001, 276: 13810-13816.PubMedGoogle Scholar
  39. Paul-Pletzer K, Yamamoto T, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, Ma J, Parness J: Probing a putative dantrolene-binding site on the cardiac ryanodine receptor. Biochem J. 2005, 387: 905-909. 10.1042/BJ20041336.PubMed CentralPubMedGoogle Scholar
  40. Wang R, Zhong X, Meng X, Koop A, Tian X, Jones PP, Fruen BR, Wagenknecht T, Liu Z, Chen SR: Localization of the dantrolene-binding sequence near the FK506-binding protein-binding site in the three-dimensional structure of the ryanodine receptor. J Biol Chem. 2011, 286: 12202-12212. 10.1074/jbc.M110.194316.PubMed CentralPubMedGoogle Scholar
  41. Kobayashi S, Yano M, Suetomi T, Ono M, Tateishi H, Mochizuki M, Xu X, Uchinoumi H, Okuda S, Yamamoto T, Koseki N, Kyushiki H, Ikemoto N, Matsuzaki M: Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol. 2009, 53: 1993-2005. 10.1016/j.jacc.2009.01.065.PubMed CentralPubMedGoogle Scholar
  42. Maxwell JT, Domeier TL, Blatter LA: Dantrolene prevents arrhythmogenic Ca2+ release in heart failure. Am J Physiol Heart Circ Physiol. 2012, 302: H953-H963. 10.1152/ajpheart.00936.2011.PubMed CentralPubMedGoogle Scholar
  43. Jung CB, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, Dorn T, Ruppenthal S, Pfeiffer S, Goedel A, Dirschinger RJ, Seyfarth M, Lam JT, Sinnecker D, Gudermann T, Lipp P, Laugwitz KL: Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med. 2012, 4: 180-191. 10.1002/emmm.201100194.PubMed CentralPubMedGoogle Scholar
  44. Zhao X, Weisleder N, Han X, Pan Z, Parness J, Brotto M, Ma J: Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. J Biol Chem. 2006, 281: 33477-33486. 10.1074/jbc.M602306200.PubMedGoogle Scholar
  45. Lanner JT, Georgiou DK, Joshi AD, Hamilton SL: Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol. 2010, 2: a003996-PubMed CentralPubMedGoogle Scholar
  46. Balshaw DM, Yamaguchi N, Meissner G: Modulation of intracellular calcium-release channels by calmodulin. J Membr Biol. 2002, 185: 1-8. 10.1007/s00232-001-0111-4.PubMedGoogle Scholar
  47. MacMillan D: FK506 binding proteins: cellular regulators of intracellular Ca2+ signalling. Eur J Pharmacol. 2013, 700: 181-193. 10.1016/j.ejphar.2012.12.029.PubMedGoogle Scholar
  48. Currie S: Cardiac ryanodine receptor phosphorylation by CaM Kinase II: keeping the balance right. Front Biosci (Landmark Ed). 2009, 14: 5134-5156. 10.2741/3591.Google Scholar
  49. Valdivia HH: Modulation of intracellular Ca2+ levels in the heart by sorcin and FKBP12, two accessory proteins of ryanodine receptors. Trends Pharmacol Sci. 1998, 19: 479-482. 10.1016/S0165-6147(98)01269-3.PubMedGoogle Scholar
  50. Zhang L, Kelley J, Schmeisser G, Kobayashi YM, Jones LR: Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. J Biol Chem. 1997, 272: 23389-23397. 10.1074/jbc.272.37.23389.PubMedGoogle Scholar
  51. Andersson DC, Betzenhauser MJ, Reiken S, Meli AC, Umanskaya A, Xie W, Shiomi T, Zalk R, Lacampagne A, Marks AR: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 2011, 14: 196-207. 10.1016/j.cmet.2011.05.014.PubMed CentralPubMedGoogle Scholar
  52. Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L, Matecki S, Lacampagne A, Marks AR: Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat Med. 2009, 15: 325-330. 10.1038/nm.1916.PubMed CentralPubMedGoogle Scholar
  53. Bellinger AM, Reiken S, Dura M, Murphy PW, Deng SX, Landry DW, Nieman D, Lehnart SE, Samaru M, LaCampagne A, Marks AR: Remodeling of ryanodine receptor complex causes “leaky” channels: a molecular mechanism for decreased exercise capacity. Proc Natl Acad Sci U S A. 2008, 105: 2198-2202. 10.1073/pnas.0711074105.PubMed CentralPubMedGoogle Scholar
  54. Fauconnier J, Meli AC, Thireau J, Roberge S, Shan J, Sassi Y, Reiken SR, Rauzier JM, Marchand A, Chauvier D, Cassan C, Crozier C, Bideaux P, Lompré AM, Jacotot E, Marks AR, Lacampagne A: Ryanodine receptor leak mediated by caspase-8 activation leads to left ventricular injury after myocardial ischemia-reperfusion. Proc Natl Acad Sci U S A. 2011, 108: 13258-13263. 10.1073/pnas.1100286108.PubMed CentralPubMedGoogle Scholar
  55. Liu X, Betzenhauser MJ, Reiken S, Meli AC, Xie W, Chen BX, Arancio O, Marks AR: Role of leaky neuronal ryanodine receptors in stress-induced cognitive dysfunction. Cell. 2012, 150: 1055-1067. 10.1016/j.cell.2012.06.052.PubMed CentralPubMedGoogle Scholar
  56. Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ: Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008, 59: 214-225. 10.1016/j.neuron.2008.06.008.PubMed CentralPubMedGoogle Scholar
  57. Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O: Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease. Science. 2008, 321: 1686-1689. 10.1126/science.1162844.PubMedGoogle Scholar
  58. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG: Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005, 280: 17294-17300. 10.1074/jbc.M500997200.PubMedGoogle Scholar
  59. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE: beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992, 12: 376-389.PubMedGoogle Scholar
  60. Simakova O, Arispe NJ: Early and late cytotoxic effects of external application of the Alzheimer’s Abeta result from the initial formation and function of Abeta ion channels. Biochemistry. 2006, 45: 5907-5915. 10.1021/bi060148g.PubMedGoogle Scholar
  61. Simakova O, Arispe NJ: The cell-selective neurotoxicity of the Alzheimer’s Abeta peptide is determined by surface phosphatidylserine and cytosolic ATP levels. membrane binding is required for Abeta toxicity. J Neurosci. 2007, 27: 13719-13729. 10.1523/JNEUROSCI.3006-07.2007.PubMedGoogle Scholar
  62. Arispe N, Rojas E, Pollard HB: Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A. 1993, 90: 567-571. 10.1073/pnas.90.2.567.PubMed CentralPubMedGoogle Scholar
  63. Ferreiro E, Oliveira CR, Pereira C: Involvement of endoplasmic reticulum Ca2+ release through ryanodine and inositol 1,4,5-triphosphate receptors in the neurotoxic effects induced by the amyloid-beta peptide. J Neurosci Res. 2004, 76: 872-880. 10.1002/jnr.20135.PubMedGoogle Scholar
  64. Niu Y, Su Z, Zhao C, Song B, Zhang X, Zhao N, Shen X, Gong Y: Effect of amyloid beta on capacitive calcium entry in neural 2a cells. Brain Res Bull. 2009, 78: 152-157. 10.1016/j.brainresbull.2008.10.003.PubMedGoogle Scholar
  65. Demuro A, Parker I: Cytotoxicity of intracellular abeta42 amyloid oligomers involves Ca2+ release from the endoplasmic reticulum by stimulated production of inositol trisphosphate. J Neurosci. 2013, 33: 3824-3833. 10.1523/JNEUROSCI.4367-12.2013.PubMed CentralPubMedGoogle Scholar
  66. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A: Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. 2010, 66: 739-754. 10.1016/j.neuron.2010.04.029.PubMed CentralPubMedGoogle Scholar
  67. Cheung KH, Shineman D, Muller M, Cardenas C, Mei L, Yang J, Tomita T, Iwatsubo T, Lee VM, Foskett JK: Mechanism of Ca2+ disruption in Alzheimer’s disease by presenilin regulation of InsP(3) receptor channel gating. Neuron. 2008, 58: 871-883. 10.1016/j.neuron.2008.04.015.PubMed CentralPubMedGoogle Scholar
  68. Ito E, Oka K, Etcheberrigaray R, Nelson TJ, McPhie DL, Tofel-Grehl B, Gibson GE, Alkon DL: Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci U S A. 1994, 91: 534-538. 10.1073/pnas.91.2.534.PubMed CentralPubMedGoogle Scholar
  69. Etcheberrigaray R, Hirashima N, Nee L, Prince J, Govoni S, Racchi M, Tanzi RE, Alkon DL: Calcium responses in fibroblasts from asymptomatic members of Alzheimer’s disease families. Neurobiol Dis. 1998, 5: 37-45. 10.1006/nbdi.1998.0176.PubMedGoogle Scholar
  70. Leissring MA, Parker I, LaFerla FM: Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals. J Biol Chem. 1999, 274: 32535-32538. 10.1074/jbc.274.46.32535.PubMedGoogle Scholar
  71. Stutzmann GE, Caccamo A, LaFerla FM, Parker I: Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer’s-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci. 2004, 24: 508-513. 10.1523/JNEUROSCI.4386-03.2004.PubMedGoogle Scholar
  72. Stutzmann GE, Smith I, Caccamo A, Oddo S, Laferla FM, Parker I: Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer’s disease mice. J Neurosci. 2006, 26: 5180-5189. 10.1523/JNEUROSCI.0739-06.2006.PubMedGoogle Scholar
  73. Green KN, Demuro A, Akbari Y, Hitt BD, Smith IF, Parker I, LaFerla FM: SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol. 2008, 181: 1107-1116. 10.1083/jcb.200706171.PubMed CentralPubMedGoogle Scholar
  74. Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I: Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer’s disease-linked mutations. Cell. 2006, 126: 981-993. 10.1016/j.cell.2006.06.059.PubMed CentralPubMedGoogle Scholar
  75. Brunello L, Zampese E, Florean C, Pozzan T, Pizzo P, Fasolato C: Presenilin-2 dampens intracellular Ca2+ stores by increasing Ca2+ leakage and reducing Ca2+ uptake. J Cell Mol Med. 2009, 13: 3358-3369. 10.1111/j.1582-4934.2009.00755.x.PubMed CentralPubMedGoogle Scholar
  76. Nelson O, Supnet C, Liu H, Bezprozvanny I: Familial Alzheimer’s disease mutations in presenilins: effects on endoplasmic reticulum calcium homeostasis and correlation with clinical phenotypes. J Alzheimers Dis. 2010, 21: 781-793.PubMedGoogle Scholar
  77. Nelson O, Tu H, Lei T, Bentahir M, de Strooper B, Bezprozvanny I: Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest. 2007, 117: 1230-1239. 10.1172/JCI30447.PubMed CentralPubMedGoogle Scholar
  78. Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I: Role of presenilins in neuronal calcium homeostasis. J Neurosci. 2010, 30: 8566-8580. 10.1523/JNEUROSCI.1554-10.2010.PubMed CentralPubMedGoogle Scholar
  79. Nelson O, Supnet C, Tolia A, Horre K, De Strooper B, Bezprozvanny I: Mutagenesis mapping of the presenilin 1 calcium leak conductance pore. J Biol Chem. 2011, 286: 22339-22347. 10.1074/jbc.M111.243063.PubMed CentralPubMedGoogle Scholar
  80. Shilling D, Mak DO, Kang DE, Foskett JK: Lack of evidence for presenilins as endoplasmic reticulum Ca2+ leak channels. J Biol Chem. 2012, 287 (14): 10933-10944. 10.1074/jbc.M111.300491.PubMed CentralPubMedGoogle Scholar
  81. Bezprozvanny I, Supnet C, Sun S, Zhang H, De Strooper B: Response to Shilling et al. J Biol Chem. 2012, 287: 20469-10.1074/jbc.L112.356790. 10.1074/jbc.M111.300491. author reply 20470PubMed CentralPubMedGoogle Scholar
  82. Das HK, Tchedre K, Mueller B: Repression of transcription of presenilin-1 inhibits gamma-secretase independent ER Ca(2)(+) leak that is impaired by FAD mutations. J Neurochem. 2012, 122: 487-500. 10.1111/j.1471-4159.2012.07794.x.PubMedGoogle Scholar
  83. Bandara S, Malmersjo S, Meyer T: Regulators of calcium homeostasis identified by inference of kinetic model parameters from live single cells perturbed by siRNA. Sci Signal. 2013, 6: ra56-PubMed CentralPubMedGoogle Scholar
  84. Furukawa K, Barger SW, Blalock EM, Mattson MP: Activation of K + channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature. 1996, 379: 74-78. 10.1038/379074a0.PubMedGoogle Scholar
  85. Cao X, Sudhof TC: A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001, 293: 115-120. 10.1126/science.1058783.PubMedGoogle Scholar
  86. Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B, Müller U, Saftig P, De Strooper B, Wolfe MS, Golde TE, LaFerla FM: A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A. 2002, 99: 4697-4702. 10.1073/pnas.072033799.PubMed CentralPubMedGoogle Scholar
  87. Pardossi-Piquard R, Checler F: The physiology of the beta-amyloid precursor protein intracellular domain AICD. J Neurochem. 2012, 120 (Suppl 1): 109-124.PubMedGoogle Scholar
  88. Raychaudhuri M, Mukhopadhyay D: AICD Overexpression in neuro 2A cells regulates expression of PTCH1 and TRPC5. Int J Alzheimers Dis. 2011, pii: 239453-doi:10.4061/2011/239453Google Scholar
  89. Chatzistavraki M, Kyratzi E, Fotinopoulou A, Papazafiri P, Efthimiopoulos S: Downregulation of AbetaPP enhances both calcium content of endoplasmic reticulum and acidic stores and the dynamics of store operated calcium channel activity. J Alzheimers Dis. 2013, 34: 407-415.PubMedGoogle Scholar
  90. Gibson GE, Vestling M, Zhang H, Szolosi S, Alkon D, Lannfelt L, Gandy S, Cowburn RF: Abnormalities in Alzheimer’s disease fibroblasts bearing the APP670/671 mutation. Neurobiol Aging. 1997, 18: 573-580. 10.1016/S0197-4580(97)00149-8.PubMedGoogle Scholar
  91. Supnet C, Grant J, Kong H, Westaway D, Mayne M: Amyloid-beta-(1–42) increases ryanodine receptor-3 expression and function in neurons of TgCRND8 mice. J Biol Chem. 2006, 281: 38440-38447. 10.1074/jbc.M606736200.PubMedGoogle Scholar
  92. Oulès B, Del Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J, Moreno S, Paterlini-Bréchot P, Trebak M, Checler F, Benfenati F, Chami M: Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. J Neurosci. 2012, 32: 11820-11834. 10.1523/JNEUROSCI.0875-12.2012.PubMed CentralPubMedGoogle Scholar
  93. Popescu BO, Cedazo-Minguez A, Benedikz E, Nishimura T, Winblad B, Ankarcrona M, Cowburn RF: Gamma-secretase activity of presenilin 1 regulates acetylcholine muscarinic receptor-mediated signal transduction. J Biol Chem. 2004, 279: 6455-6464.PubMedGoogle Scholar
  94. Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM: Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer’s disease. J Neurochem. 2005, 94: 1711-1718. 10.1111/j.1471-4159.2005.03332.x.PubMedGoogle Scholar
  95. Chan SL, Mayne M, Holden CP, Geiger JD, Mattson MP: Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem. 2000, 275: 18195-18200. 10.1074/jbc.M000040200.PubMedGoogle Scholar
  96. Lee SY, Hwang DY, Kim YK, Lee JW, Shin IC, Oh KW, Lee MK, Lim JS, Yoon DY, Hwang SJ, Hong JT: PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase-3 by enhancing of ryanodine receptor-mediated calcium release. FASEB J. 2006, 20: 151-153. 10.1096/fj.05-4017fje;1.PubMedGoogle Scholar
  97. Wu B, Yamaguchi H, Lai FA, Shen J: Presenilins regulate calcium homeostasis and presynaptic function via ryanodine receptors in hippocampal neurons. Proc Natl Acad Sci U S A. 2013, 110: 15091-15096. 10.1073/pnas.1304171110.PubMed CentralPubMedGoogle Scholar
  98. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, Kandel ER, Duff K, Kirkwood A, Shen J: Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004, 42: 23-36. 10.1016/S0896-6273(04)00182-5.PubMedGoogle Scholar
  99. Zhang C, Wu B, Beglopoulos V, Wines-Samuelson M, Zhang D, Dragatsis I, Sudhof TC, Shen J: Presenilins are essential for regulating neurotransmitter release. Nature. 2009, 460: 632-636. 10.1038/nature08177.PubMed CentralPubMedGoogle Scholar
  100. Chakroborty S, Goussakov I, Miller MB, Stutzmann GE: Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J Neurosci. 2009, 29: 9458-9470. 10.1523/JNEUROSCI.2047-09.2009.PubMedGoogle Scholar
  101. Kipanyula MJ, Contreras L, Zampese E, Lazzari C, Wong AK, Pizzo P, Fasolato C, Pozzan T: Ca2+ dysregulation in neurons from transgenic mice expressing mutant presenilin 2. Aging Cell. 2012, 11: 885-893. 10.1111/j.1474-9726.2012.00858.x.PubMedGoogle Scholar
  102. Goussakov I, Miller MB, Stutzmann GE: NMDA-mediated Ca(2+) influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice. J Neurosci. 2010, 30: 12128-12137. 10.1523/JNEUROSCI.2474-10.2010.PubMed CentralPubMedGoogle Scholar
  103. Lopez JR, Lyckman A, Oddo S, Laferla FM, Querfurth HW, Shtifman A: Increased intraneuronal resting [Ca(2+)] in adult Alzheimer’s disease mice. J Neurochem. 2008, 105 (1): 262-271. 10.1111/j.1471-4159.2007.05135.x.PubMedGoogle Scholar
  104. Rojas G, Cardenas AM, Fernandez-Olivares P, Shimahara T, Segura-Aguilar J, Caviedes R, Caviedes P: Effect of the knockdown of amyloid precursor protein on intracellular calcium increases in a neuronal cell line derived from the cerebral cortex of a trisomy 16 mouse. Exp Neurol. 2008, 209: 234-242. 10.1016/j.expneurol.2007.09.024.PubMedGoogle Scholar
  105. Paula-Lima AC, Hidalgo C: Amyloid beta-peptide oligomers, ryanodine receptor-mediated Ca(2+) release, and Wnt-5a/Ca(2+) signaling: opposing roles in neuronal mitochondrial dynamics?. Front Cell Neurosci. 2013, 7: 120-PubMed CentralPubMedGoogle Scholar
  106. Shtifman A, Ward CW, Laver DR, Bannister ML, Lopez JR, Kitazawa M, LaFerla FM, Ikemoto N, Querfurth HW: Amyloid-beta protein impairs Ca2+ release and contractility in skeletal muscle. Neurobiol Aging. 2010, 31: 2080-2090. 10.1016/j.neurobiolaging.2008.11.003.PubMed CentralPubMedGoogle Scholar
  107. Kelliher M, Fastbom J, Cowburn RF, Bonkale W, Ohm TG, Ravid R, Sorrentino V, O’Neill C: Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer’s disease neurofibrillary and beta-amyloid pathologies. Neuroscience. 1999, 92: 499-513. 10.1016/S0306-4522(99)00042-1.PubMedGoogle Scholar
  108. Bruno AM, Huang JY, Bennett DA, Marr RA, Hastings ML, Stutzmann GE: Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging. 2012, 33: 1001-1006.PubMed CentralPubMedGoogle Scholar
  109. Antonell A, Lladó A, Altirriba J, Botta-Orfila T, Balasa M, Fernández M, Ferrer I, Sánchez-Valle R, Molinuevo JL: A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer’s disease. Neurobiol Aging. 2013, 34: 1772-1778. 10.1016/j.neurobiolaging.2012.12.026.PubMedGoogle Scholar
  110. Stutzmann GE, Smith I, Caccamo A, Oddo S, Parker I, Laferla F: Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Ann N Y Acad Sci. 2007, 1097: 265-277. 10.1196/annals.1379.025.PubMedGoogle Scholar
  111. Liu J, Supnet C, Sun S, Zhang H, Good L, Popugaeva E, Bezprozvanny I: The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease. Channels (Austin). 2014, 8 (3): [Epub ahead of print]Google Scholar
  112. Paula-Lima AC, Adasme T, SanMartin C, Sebollela A, Hetz C, Carrasco MA, Ferreira ST, Hidalgo C: Amyloid beta-peptide oligomers stimulate RyR-mediated Ca2+ release inducing mitochondrial fragmentation in hippocampal neurons and prevent RyR-mediated dendritic spine remodeling produced by BDNF. Antioxid Redox Signal. 2011, 14: 1209-1223. 10.1089/ars.2010.3287.PubMedGoogle Scholar
  113. Chami L, Checler F: BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer’s disease. Mol Neurodegener. 2012, 7: 52-10.1186/1750-1326-7-52.PubMed CentralPubMedGoogle Scholar
  114. Casas-Tinto S, Zhang Y, Sanchez-Garcia J, Gomez-Velazquez M, Rincon-Limas DE, Fernandez-Funez P: The ER stress factor XBP1s prevents amyloid-beta neurotoxicity. Hum Mol Genet. 2011, 20: 2144-2160. 10.1093/hmg/ddr100.PubMed CentralPubMedGoogle Scholar
  115. Takeda T, Asahi M, Yamaguchi O, Hikoso S, Nakayama H, Kusakari Y, Kawai M, Hongo K, Higuchi Y, Kashiwase K, Watanabe T, Taniike M, Nakai A, Nishida K, Kurihara S, Donoviel DB, Bernstein A, Tomita T, Iwatsubo T, Hori M, Otsu K: Presenilin 2 regulates the systolic function of heart by modulating Ca2+ signaling. FASEB J. 2005, 19: 2069-2071.PubMedGoogle Scholar
  116. Hayrapetyan V, Rybalchenko V, Rybalchenko N, Koulen P: The N-terminus of presenilin-2 increases single channel activity of brain ryanodine receptors through direct protein-protein interaction. Cell Calcium. 2008, 44: 507-518. 10.1016/j.ceca.2008.03.004.PubMedGoogle Scholar
  117. Rybalchenko V, Hwang SY, Rybalchenko N, Koulen P: The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. Int J Biochem Cell Biol. 2008, 40: 84-97. 10.1016/j.biocel.2007.06.023.PubMedGoogle Scholar
  118. Pack-Chung E, Meyers MB, Pettingell WP, Moir RD, Brownawell AM, Cheng I, Tanzi RE, Kim TW: Presenilin 2 interacts with sorcin, a modulator of the ryanodine receptor. J Biol Chem. 2000, 275: 14440-14445. 10.1074/jbc.M909882199.PubMedGoogle Scholar
  119. Bull R, Finkelstein JP, Galvez J, Sanchez G, Donoso P, Behrens MI, Hidalgo C: Ischemia enhances activation by Ca2+ and redox modification of ryanodine receptor channels from rat brain cortex. J Neurosci. 2008, 28: 9463-9472. 10.1523/JNEUROSCI.2286-08.2008.PubMedGoogle Scholar
  120. Gant JC, Chen KC, Norris CM, Kadish I, Thibault O, Blalock EM, Porter NM, Landfield PW: Disrupting function of FK506-binding protein 1b/12.6 induces the Ca(2) + −dysregulation aging phenotype in hippocampal neurons. J Neurosci. 2011, 31: 1693-1703. 10.1523/JNEUROSCI.4805-10.2011.PubMed CentralPubMedGoogle Scholar
  121. Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, Mavros C, Beyreuther K, Carrington D, Masters CL, Cherny RA, Cappai R, Bush AI: Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer’s disease beta-amyloid. FASEB J. 2004, 18: 1427-1429.PubMedGoogle Scholar
  122. Emerit J, Edeas M, Bricaire F: Neurodegenerative diseases and oxidative stress. Biomed Pharmacother. 2004, 58: 39-46.PubMedGoogle Scholar
  123. Lin MT, Beal MF: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006, 443: 787-795. 10.1038/nature05292.PubMedGoogle Scholar
  124. Su Y, Ryder J, Ni B: Inhibition of Abeta production and APP maturation by a specific PKA inhibitor. FEBS Lett. 2003, 546: 407-410. 10.1016/S0014-5793(03)00645-8.PubMedGoogle Scholar
  125. Marambaud P, Chevallier N, Ancolio K, Checler F: Post-transcriptional contribution of a cAMP-dependent pathway to the formation of alpha- and beta/gamma-secretases-derived products of beta APP maturation in human cells expressing wild-type and Swedish mutated beta APP. Mol Med. 1998, 4: 715-723.PubMed CentralPubMedGoogle Scholar
  126. Marambaud P, Ancolio K, Alves da Costa C, Checler F: Effect of protein kinase A inhibitors on the production of Abeta40 and Abeta42 by human cells expressing normal and Alzheimer’s disease-linked mutated betaAPP and presenilin 1. Br J Pharmacol. 1999, 126: 1186-1190. 10.1038/sj.bjp.0702406.PubMed CentralPubMedGoogle Scholar
  127. Ueda K, Yagami T, Kageyama H, Kawasaki K: Protein kinase inhibitor attenuates apoptotic cell death induced by amyloid beta protein in culture of the rat cerebral cortex. Neurosci Lett. 1996, 203: 175-178. 10.1016/0304-3940(95)12288-5.PubMedGoogle Scholar
  128. Eftekharzadeh B, Ramin M, Khodagholi F, Moradi S, Tabrizian K, Sharif R, Azami K, Beyer C, Sharifzadeh M: Inhibition of PKA attenuates memory deficits induced by beta-amyloid (1–42), and decreases oxidative stress and NF-kappaB transcription factors. Behav Brain Res. 2012, 226: 301-308. 10.1016/j.bbr.2011.08.015.PubMedGoogle Scholar
  129. Hui L, Hong Y, Jingjing Z, Yuan H, Qi C, Nong Z: HGF suppresses high glucose-mediated oxidative stress in mesangial cells by activation of PKG and inhibition of PKA. Free Radic Biol Med. 2010, 49: 467-473. 10.1016/j.freeradbiomed.2010.05.002.PubMedGoogle Scholar
  130. Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC, Landfield PW: Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci. 2003, 23: 3807-3819.PubMedGoogle Scholar
  131. Buxbaum JD, Ruefli AA, Parker CA, Cypess AM, Greengard P: Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc Natl Acad Sci U S A. 1994, 91: 4489-4493. 10.1073/pnas.91.10.4489.PubMed CentralPubMedGoogle Scholar
  132. Querfurth HW, Selkoe DJ: Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry. 1994, 33: 4550-4561. 10.1021/bi00181a016.PubMedGoogle Scholar
  133. Querfurth HW, Jiang J, Geiger JD, Selkoe DJ: Caffeine stimulates amyloid beta-peptide release from beta-amyloid precursor protein-transfected HEK293 cells. J Neurochem. 1997, 69: 1580-1591.PubMedGoogle Scholar
  134. Peng J, Liang G, Inan S, Wu Z, Joseph DJ, Meng Q, Peng Y, Eckenhoff MF, Wei H: Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. Neurosci Lett. 2012, 516: 274-279. 10.1016/j.neulet.2012.04.008.PubMed CentralPubMedGoogle Scholar
  135. Chakroborty S, Briggs C, Miller MB, Goussakov I, Schneider C, Kim J, Wicks J, Richardson JC, Conklin V, Cameransi BG, Stutzmann GE: Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer’s disease. PLoS One. 2012, 7: e52056-10.1371/journal.pone.0052056.PubMed CentralPubMedGoogle Scholar
  136. Popescu BO, Oprica M, Sajin M, Stanciu CL, Bajenaru O, Predescu A, Vidulescu C, Popescu LM: Dantrolene protects neurons against kainic acid induced apoptosis in vitro and in vivo. J Cell Mol Med. 2002, 6: 555-569. 10.1111/j.1582-4934.2002.tb00454.x.PubMedGoogle Scholar
  137. Wei H, Perry DC: Dantrolene is cytoprotective in two models of neuronal cell death. J Neurochem. 1996, 67: 2390-2398.PubMedGoogle Scholar
  138. Nakayama R, Yano T, Ushijima K, Abe E, Terasaki H: Effects of dantrolene on extracellular glutamate concentration and neuronal death in the rat hippocampal CA1 region subjected to transient ischemia. Anesthesiology. 2002, 96: 705-710. 10.1097/00000542-200203000-00029.PubMedGoogle Scholar
  139. Chen X, Wu J, Lvovskaya S, Herndon E, Supnet C, Bezprozvanny I: Dantrolene is neuroprotective in Huntington’s disease transgenic mouse model. Mol Neurodegener. 2011, 6: 81-10.1186/1750-1326-6-81.PubMed CentralPubMedGoogle Scholar
  140. Suzuki M, Nagai Y, Wada K, Koike T: Calcium leak through ryanodine receptor is involved in neuronal death induced by mutant huntingtin. Biochem Biophys Res Commun. 2012, 429: 18-23. 10.1016/j.bbrc.2012.10.107.PubMedGoogle Scholar
  141. Chen X, Tang TS, Tu H, Nelson O, Pook M, Hammer R, Nukina N, Bezprozvanny I: Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J Neurosci. 2008, 28: 12713-12724. 10.1523/JNEUROSCI.3909-08.2008.PubMed CentralPubMedGoogle Scholar
  142. Liu J, Tang TS, Tu H, Nelson O, Herndon E, Huynh DP, Pulst SM, Bezprozvanny I: Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci. 2009, 29: 9148-9162. 10.1523/JNEUROSCI.0660-09.2009.PubMed CentralPubMedGoogle Scholar
  143. Frandsen A, Schousboe A: Dantrolene prevents glutamate cytotoxicity and Ca2+ release from intracellular stores in cultured cerebral cortical neurons. J Neurochem. 1991, 56: 1075-1078. 10.1111/j.1471-4159.1991.tb02031.x.PubMedGoogle Scholar
  144. Bouchelouche P, Belhage B, Frandsen A, Drejer J, Schousboe A: Glutamate receptor activation in cultured cerebellar granule cells increases cytosolic free Ca2+ by mobilization of cellular Ca2+ and activation of Ca2+ influx. Exp Brain Res. 1989, 76: 281-291.PubMedGoogle Scholar
  145. Guo Q, Sopher BL, Furukawa K, Pham DG, Robinson N, Martin GM, Mattson MP: Alzheimer’s presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. J Neurosci. 1997, 17: 4212-4222.PubMedGoogle Scholar
  146. Imaizumi K, Morihara T, Mori Y, Katayama T, Tsuda M, Furuyama T, Wanaka A, Takeda M, Tohyama M: The cell death-promoting gene DP5, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid beta protein. J Biol Chem. 1999, 274: 7975-7981. 10.1074/jbc.274.12.7975.PubMedGoogle Scholar
  147. Supnet C, Noonan C, Richard K, Bradley J, Mayne M: Up-regulation of the type 3 ryanodine receptor is neuroprotective in the TgCRND8 mouse model of Alzheimer’s disease. J Neurochem. 2010, 112: 356-365. 10.1111/j.1471-4159.2009.06487.x.PubMedGoogle Scholar
  148. Ghosh A, Greenberg ME: Calcium signaling in neurons: molecular mechanisms and cellular consequences. Science. 1995, 268: 239-247. 10.1126/science.7716515.PubMedGoogle Scholar
  149. Trinchese F, Fa M, Liu S, Zhang H, Hidalgo A, Schmidt SD, Yamaguchi H, Yoshii N, Mathews PM, Nixon RA, Arancio O: Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest. 2008, 118: 2796-2807. 10.1172/JCI34254.PubMed CentralPubMedGoogle Scholar
  150. Grynspan F, Griffin WR, Cataldo A, Katayama S, Nixon RA: Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer’s disease. Brain Res. 1997, 763: 145-158. 10.1016/S0006-8993(97)00384-3.PubMedGoogle Scholar
  151. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, McKeon F, Bobo T, Franke TF, Reed JC: Ca2 + −induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999, 284: 339-343. 10.1126/science.284.5412.339.PubMedGoogle Scholar
  152. Dineley KT, Hogan D, Zhang WR, Taglialatela G: Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem. 2007, 88: 217-224. 10.1016/j.nlm.2007.03.010.PubMed CentralPubMedGoogle Scholar
  153. Cardoso SM, Oliveira CR: The role of calcineurin in amyloid-beta-peptides-mediated cell death. Brain Res. 2005, 1050: 1-7. 10.1016/j.brainres.2005.04.078.PubMedGoogle Scholar
  154. Malenka RC, Bear MF: LTP and LTD: an embarrassment of riches. Neuron. 2004, 44: 5-21. 10.1016/j.neuron.2004.09.012.PubMedGoogle Scholar
  155. Bardo S, Cavazzini MG, Emptage N: The role of the endoplasmic reticulum Ca2+ store in the plasticity of central neurons. Trends Pharmacol Sci. 2006, 27: 78-84. 10.1016/j.tips.2005.12.008.PubMedGoogle Scholar
  156. Bouchard R, Pattarini R, Geiger JD: Presence and functional significance of presynaptic ryanodine receptors. Prog Neurobiol. 2003, 69: 391-418. 10.1016/S0301-0082(03)00053-4.PubMedGoogle Scholar
  157. Zucker RS, Regehr WG: Short-term synaptic plasticity. Annu Rev Physiol. 2002, 64: 355-405. 10.1146/annurev.physiol.64.092501.114547.PubMedGoogle Scholar
  158. Yuste R, Majewska A, Holthoff K: From form to function: calcium compartmentalization in dendritic spines. Nat Neurosci. 2000, 3: 653-659. 10.1038/76609.PubMedGoogle Scholar
  159. Raymond CR, Redman SJ: Spatial segregation of neuronal calcium signals encodes different forms of LTP in rat hippocampus. J Physiol. 2006, 570: 97-111. 10.1113/jphysiol.2005.098947.PubMed CentralPubMedGoogle Scholar
  160. Obenaus A, Mody I, Baimbridge KG: Dantrolene-Na (Dantrium) blocks induction of long-term potentiation in hippocampal slices. Neurosci Lett. 1989, 98: 172-178. 10.1016/0304-3940(89)90505-3.PubMedGoogle Scholar
  161. Harvey J, Collingridge GL: Thapsigargin blocks the induction of long-term potentiation in rat hippocampal slices. Neurosci Lett. 1992, 139: 197-200. 10.1016/0304-3940(92)90551-H.PubMedGoogle Scholar
  162. Nishiyama M, Hong K, Mikoshiba K, Poo MM, Kato K: Calcium stores regulate the polarity and input specificity of synaptic modification. Nature. 2000, 408: 584-588. 10.1038/35046067.PubMedGoogle Scholar
  163. Fitzjohn SM, Collingridge GL: Calcium stores and synaptic plasticity. Cell Calcium. 2002, 32: 405-411. 10.1016/S0143416002001999.PubMedGoogle Scholar
  164. Shimuta M, Yoshikawa M, Fukaya M, Watanabe M, Takeshima H, Manabe T: Postsynaptic modulation of AMPA receptor-mediated synaptic responses and LTP by the type 3 ryanodine receptor. Mol Cell Neurosci. 2001, 17: 921-930. 10.1006/mcne.2001.0981.PubMedGoogle Scholar
  165. Futatsugi A, Kato K, Ogura H, Li ST, Nagata E, Kuwajima G, Tanaka K, Itohara S, Mikoshiba K: Facilitation of NMDAR-independent LTP and spatial learning in mutant mice lacking ryanodine receptor type 3. Neuron. 1999, 24: 701-713. 10.1016/S0896-6273(00)81123-X.PubMedGoogle Scholar
  166. Stutzmann GE, LaFerla FM, Parker I: Ca2+ signaling in mouse cortical neurons studied by two-photon imaging and photoreleased inositol triphosphate. J Neurosci. 2003, 23: 758-765.PubMedGoogle Scholar
  167. Chakroborty S, Stutzmann GE: Early calcium dysregulation in Alzheimer’s disease: setting the stage for synaptic dysfunction. Sci China Life Sci. 2011, 54: 752-762. 10.1007/s11427-011-4205-7.PubMedGoogle Scholar
  168. Chakroborty S, Kim J, Schneider C, Jacobson C, Molgo J, Stutzmann GE: Early presynaptic and postsynaptic calcium signaling abnormalities mask underlying synaptic depression in presymptomatic Alzheimer’s disease mice. J Neurosci. 2012, 32: 8341-8353. 10.1523/JNEUROSCI.0936-12.2012.PubMed CentralPubMedGoogle Scholar
  169. Ziviani E, Lippi G, Bano D, Munarriz E, Guiducci S, Zoli M, Young KW, Nicotera P: Ryanodine receptor-2 upregulation and nicotine-mediated plasticity. EMBO J. 2011, 30: 194-204. 10.1038/emboj.2010.279.PubMed CentralPubMedGoogle Scholar
  170. Zhao W, Meiri N, Xu H, Cavallaro S, Quattrone A, Zhang L, Alkon DL: Spatial learning induced changes in expression of the ryanodine type II receptor in the rat hippocampus. FASEB J. 2000, 14: 290-300.PubMedGoogle Scholar
  171. Matsuo N, Tanda K, Nakanishi K, Yamasaki N, Toyama K, Takao K, Takeshima H, Miyakawa T: Comprehensive behavioral phenotyping of ryanodine receptor type 3 (RyR3) knockout mice: decreased social contact duration in two social interaction tests. Front Behav Neurosci. 2009, 3: 3-PubMed CentralPubMedGoogle Scholar
  172. Alkon DL, Nelson TJ, Zhao W, Cavallaro S: Time domains of neuronal Ca2+ signaling and associative memory: steps through a calexcitin, ryanodine receptor, K + channel cascade. Trends Neurosci. 1998, 21: 529-537. 10.1016/S0166-2236(98)01277-6.PubMedGoogle Scholar
  173. Elias GM, Elias LA, Apostolides PF, Kriegstein AR, Nicoll RA: Differential trafficking of AMPA and NMDA receptors by SAP102 and PSD-95 underlies synapse development. Proc Natl Acad Sci U S A. 2008, 105: 20953-20958. 10.1073/pnas.0811025106.PubMed CentralPubMedGoogle Scholar
  174. Tollefson GD: Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry. 1990, 27: 1133-1142. 10.1016/0006-3223(90)90050-C.PubMedGoogle Scholar
  175. Bullock R: Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Alzheimer Dis Assoc Disord. 2006, 20: 23-29. 10.1097/01.wad.0000201847.29836.a5.PubMedGoogle Scholar

Copyright

© Del Prete et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement